Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYR | P14679 | 1/20 | 0.60 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.55 |
| ▸ | CYP19A1 | P11511 | 5/20 | 0.54 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.49 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.47 |
| ▸ | JAK2 | O60674 | 1/20 | 0.46 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.46 |
| ▸ | KDR | P35968 | 1/20 | 0.46 |
| ▸ | GSK3B | P49841 | 1/20 | 0.46 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.46 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16216237 | 0.86 | CYP19A1 (0.74) | TYRNOTUMCYP19A1HSP90AB1JAK2 | |
| SCHEMBL16218784 | 0.86 | TYR (0.60) | TYRNOTUMCYP19A1KCNMA1HSP90AB1 | |
| SCHEMBL21557005 | 0.84 | TYR (0.58) | TYRNOTUMCYP19A1HSP90AB1HDAC1 | |
| SCHEMBL16401421 | 0.80 | TYR (0.59) | TYRNOTUMCYP19A1KCNMA1JAK2 | |
| SCHEMBL16831504 | 0.77 | CYP19A1 (0.69) | NOTUMCYP19A1HSP90AB1HDAC1HRH4 | |
| SCHEMBL9969547 | 0.77 | HDAC1 (0.61) | NOTUMCYP19A1HDAC1 | |
| SCHEMBL19941362 | 0.77 | NOTUM (0.56) | NOTUMCYP19A1HSP90AB1HDAC1 | |
| SCHEMBL15796292 | 0.75 | CYP19A1 (0.72) | NOTUMCYP19A1HSP90AB1HDAC1HRH4 | |
| SCHEMBL10660863 | 0.75 | TYR (0.54) | TYRCYP19A1HDAC1JAK2ROCK2 | |
| SCHEMBL15795903 | 0.74 | CYP19A1 (0.74) | CYP19A1HSP90AB1HDAC1HRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200397927-A1 | COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS | LANTHEUS MEDICAL IMAGING, INC. (US) | 2020-12-24 | — | — | US | disclosed |
| US-20170266326-A1 | COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS | LANTHEUS MEDICAL IMAGING, INC. (US) | 2017-09-21 | — | — | US | disclosed |
| US-9550000-B2 | Compositions, methods, and systems for the synthesis and use of imaging agents | LANTHEUS MEDICAL IMAGING, INC. (US) | 2017-01-24 | — | — | US | disclosed |
| US-20140328756-A1 | COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS | LANTHEUS MEDICAL IMAGING, INC. (US) | 2014-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170266326-A1 | COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS | FABP3, TNNI3, TNNT2 | TYR 1231/4885NOTUM 2096/4885CYP19A1 2566/4885 |
| US-20140328756-A1 | COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS | FABP3, TNNI3, TNNT2 | TYR 1231/4885NOTUM 2096/4885CYP19A1 2566/4885 |
| US-20200397927-A1 | COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS | FABP3, TNNI3, TNNT2 | TYR 1231/4885NOTUM 2096/4885CYP19A1 2566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.